Chronic ketamine administration modulates midbrain dopamine system in mice

PLoS One. 2012;7(8):e43947. doi: 10.1371/journal.pone.0043947. Epub 2012 Aug 24.

Abstract

Ketamine is an anesthetic and a popular abusive drug. As an anesthetic, effects of ketamine on glutamate and GABA transmission have been well documented but little is known about its long-term effects on the dopamine system. In the present study, the effects of ketamine on dopamine were studied in vitro and in vivo. In pheochromocytoma (PC 12) cells and NGF differentiated-PC 12 cells, ketamine decreased the cell viability while increasing dopamine (DA) concentrations in a dose-related manner. However, ketamine did not affect the expression of genes involved in DA synthesis. In the long-term (3 months) ketamine treated mice, significant increases of DA contents were found in the midbrain. Increased DA concentrations were further supported by up-regulation of tyrosine hydroxylase (TH), the rate limiting enzyme in catecholamine synthesis. Activation of midbrain dopaminergic neurons could be related to ketamine modulated cortical-subcortical glutamate connections. Using western blotting, significant increases in BDNF protein levels were found in the midbrain, suggesting that perhaps BDNF pathways in the cortical-subcortical connections might contribute to the long-term ketamine induced TH upregulation. These data suggest that long-term ketamine abuse caused a delayed and persistent upregulation of subcortical DA systems, which may contribute to the altered mental status in ketamine abusers.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Brain-Derived Neurotrophic Factor / metabolism
  • Dopamine / metabolism*
  • Dopaminergic Neurons / drug effects*
  • Dopaminergic Neurons / metabolism
  • Dose-Response Relationship, Drug
  • Excitatory Amino Acid Antagonists / administration & dosage*
  • Ketamine / administration & dosage*
  • Mesencephalon / drug effects*
  • Mesencephalon / metabolism
  • Mice
  • PC12 Cells
  • Rats
  • Tyrosine 3-Monooxygenase / metabolism
  • Up-Regulation / drug effects

Substances

  • Brain-Derived Neurotrophic Factor
  • Excitatory Amino Acid Antagonists
  • Ketamine
  • Tyrosine 3-Monooxygenase
  • Dopamine

Grants and funding

This work was supported by the Beat Drugs Fund Association (100052), Hong Kong Government. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.